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thrombosis were acute coronary syndrome at admission, diabetes, and stent
number/length. Age, extent of coronary disease, renal failure and smoking also
appeared as significant predictors, but less consistently. Premature discontinuation
of dual antiplatelet therapy was also a powerful predictor of stent thrombosis.
Conclusions: Despite numerous possible risk factors, the strongest predic-
tors of stent thrombosis are diabetes, acute coronary syndromes, stent length/
number, and premature discontinuation of dual antiplatelet therapy.
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Objectives: To assess the impact on 6-month post-stenting outcomes of
long-term vitamin K antagonist (VKA) therapy at baseline and of continued
versus discontinued VKA therapy.
Background: Dual antiplatelet therapy (DAT) after stenting is associated with
higher bleeding event rates in patients on long-term VKA therapy at stenting.
Methods: Matched case-control study in patients who underwent stenting
at four centers between July 2003 and October 2006. Matching was on age,
sex, and clinical presentation.
Results: We included 181 patients on VKA therapy at stenting and 181 con-
trols. VKA therapy was continued after stenting in 60% of the cases. The 6-month
major adverse event rate (primary endpoint defined as the association of death,
myocardial infarction, stent thrombosis, major bleeding or stroke) was signifi-
cantly higher in the cases than in the controls (odds ratio [OR], 3.3; 95% confi-
dence interval [95%CI], 1.5-6.9; P<0.01). The cases had higher rates of death
(OR, 3.8; 95%CI, 1.0-14.0; P=0.05) and major bleeding (OR, 5.4; 95%CI, 1.5-
18.9; P<0.01). DAT duration was significantly shorter in the cases left on VKA
therapy but did not differ according to stent type. By multivariable analysis, sig-
nificant predictors of the MAE rate in the cases were GpIIb3a treatment during
stenting (hazard ratio [HR], 7.4; 95%CI, 1.8-29.7; P<0.01) and age (HR per year
1.05; 95%CI, 1.0-1.1; P=0.03). There was a non significant reduction in MAE and
major bleeding for cases at 6 months if VKA therapy were continued in associa-
tion with DAT after stenting (rate of MAE: 8.3 vs. 15.7% for discontinued VKA
therapy, p=0.26, rate of major bleeding 3.8 vs 9.7 p=0.16). 
Conclusions: Long-term VKA therapy at stenting is associated with
increased bleeding events and poor outcomes. Continued VKA therapy with
close INR monitoring and a short DAT duration may be appropriate in
patients on long-term VKA therapy at stenting.
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Objectives and background: Loss-of-Function allele CYP2C19*2 has
been associated with impaired clopidogrel response and worse prognosis in
clopidogrel-treated patients. Benefit of Tailored therapy according to platelet
function test remains unclear and potential effect of genotypes on this benefit
has not been addressed in unstable patients. The present study was designed
to evaluate the benefit of tailored therapy with higher maintenance dose
according to CYP2C19 genotypes in patients identified as non responders
undergoing Percutaneous Coronary Intervention (PCI) for Non ST segment
Elevation Acute Coronary Syndrome (NSTE ACS). 
Methods and results: 346 consecutive patients were enrolled, who
received loading dose of 600 mg, including 86 *2 Carriers (13 homozygotes
and 73 heterozygotes) and 260 *2 Non Carriers. Clopidogrel response,
assessed with Platelet Reactivity Index VASP (PRI VASP), was significantly
affected by genotypes with lower Clopidogrel Response in CYP2C19*2 allele
carriers (p=0.01). Accordingly, the rate of clopidogrel non responders was
higher in CYP2C19*2 allele carriers: 53% vs. 41%, p=0.04. All Clopidogrel
non Responders (n=151), including 105 *2 Non Carriers and 46 *2 Carriers,
received High 150 mg clopidogrel maintenance at discharge to overcome ini-
tial non response. After one month, High Maintenance dose overcame clopi-
dogrel non response in only 44 % of the whole population and significantly
less frequently in *2 Carriers than in Non Carriers, 28% vs. 50%, p=0.01.
Conclusion: Higher Clopidogrel Maintenance dose was able to overcome
Clopidogrel Non Response in less than half of Clopidogrel Non Responders
undergoing PCI for NSTE ACS. The benefit of this tailored Therapy was sig-
nificantly reduced in CYP2C19*2 Carriers. Therefore, these patients might
require alternative strategies with new P2Y12 blockers.
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Objective: To investigate the relationship between fragmented QRS com-
plex (fQRS) and parameters of infarct size (IS) and no reflow assessed by car-
diac magnetic resonance (CMR) in patients with acute myocardial infarction.
Patients and methods: Patients with a fQRS were compared with patients
without fQRS. CMR was performed in 246 consecutive patients within the
week following the AMI. Early and late gadolinium-enhanced images were
examined to assess IS and microvascular obstruction. Left ventricular ejection
fraction (LVEF) and left ventricular volumes were also determined.
Results: 128 (52%) presented a fQRS on the first 12-lead ECG 36 hours
post-AMI. Despite similar demographic, ECG and clinical features, patients
with a fQRS were more likely to be male and had a higher systolic blood pres-
sure on admission. Furthermore, patients with a fQRS had a significantly
lower LVEF, and larger IS than did patients without fQRS as assessed by
CMR. Interestingly, myocardial perfusion abnormalities after infarction deter-
mined by first-pass perfusion images (microvascular obstruction=MO) and
late perfusion images (persistent MO=PMO) were significantly more frequent
in the fQRS group (Table 1). By multivariate logistic regression analysis, only
infarct size (OR=0.456; 95%CI: 1.03-1.07, p=0.001) was an independent pre-
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